Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda Jw Bosch, Gerrit A Meijer and 3 more
Open access · greenAbstract readRandomized Controlled Trial
Trial report in Epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 7 institutions in 3 countries.
Lynn SymondsDivision of Oncology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4989-4602
Ming YuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
YuHong ZhangClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fang-Shu OuAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Tyler J ZemlaAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Kelly CarterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-1772-9431
Monica BertagnolliOffice of the Alliance Group Chair, Boston, MA, USA.
Federico InnocentiDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Linda Jw BoschDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Gerrit A MeijerDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-0057-0938
Beatriz CarvalhoDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
William M GradyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Stacey A CohenDivision of Oncology, University of Washington, Seattle, WA, USA.
The Netherlands Cancer Institute · NLUniversity of Washington · USFred Hutch Cancer Center · USMayo Clinic · USBrigham and Women's Hospital · USGuangxi Medical University · CNUniversity of North Carolina at Chapel Hill · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
Tumor mutation signaturesP01CA077852 · NCI · UNIVERSITY OF WASHINGTON · PI SIDOROVA, JULIA · 1999 to 2019
$26.0M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
Trans-NetworkU54CA143862 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI DAVIES, PAUL · 2009 to 2013
$8.4M
Hutchinson Center as Lead Academic Participating Site (UG1)UG1CA233328 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Yu · 2019 to 2026
Aberrantly methylated genes contribute to the landscape of epigenetic alterations in colorectal adenocarcinoma. The global CpG Island methylator phenotype (CIMP) and individually methylated genes are potential prognostic/predictive biomarkers. Research suggests an association between methylated
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). · full record | OpenQuestion